ATE466093T1 - Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer - Google Patents

Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer

Info

Publication number
ATE466093T1
ATE466093T1 AT04745818T AT04745818T ATE466093T1 AT E466093 T1 ATE466093 T1 AT E466093T1 AT 04745818 T AT04745818 T AT 04745818T AT 04745818 T AT04745818 T AT 04745818T AT E466093 T1 ATE466093 T1 AT E466093T1
Authority
AT
Austria
Prior art keywords
associated virus
virus vector
alzheimer
disease
treatment
Prior art date
Application number
AT04745818T
Other languages
English (en)
Inventor
Takeshi Tabira
Hideo National Hara
Original Assignee
Japan Government
Nat Inst Of Biomedical Innovat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Government, Nat Inst Of Biomedical Innovat filed Critical Japan Government
Application granted granted Critical
Publication of ATE466093T1 publication Critical patent/ATE466093T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04745818T 2003-06-13 2004-06-11 Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer ATE466093T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003169714 2003-06-13
JP2003371103A JP4888876B2 (ja) 2003-06-13 2003-10-30 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
PCT/JP2004/008224 WO2004111250A1 (ja) 2003-06-13 2004-06-11 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター

Publications (1)

Publication Number Publication Date
ATE466093T1 true ATE466093T1 (de) 2010-05-15

Family

ID=33554414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04745818T ATE466093T1 (de) 2003-06-13 2004-06-11 Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer

Country Status (15)

Country Link
US (1) US8318687B2 (de)
EP (1) EP1634956B1 (de)
JP (1) JP4888876B2 (de)
KR (1) KR20060029225A (de)
AT (1) ATE466093T1 (de)
AU (1) AU2004248014B2 (de)
BR (1) BRPI0411321A (de)
CA (1) CA2529179C (de)
DE (1) DE602004026867D1 (de)
DK (1) DK1634956T3 (de)
ES (1) ES2345151T3 (de)
NZ (1) NZ544554A (de)
PT (1) PT1634956E (de)
RU (1) RU2335542C2 (de)
WO (1) WO2004111250A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI349001B (en) 2005-03-18 2011-09-21 Lg Chemical Ltd Method of producing unsaturated acid from olefin
CN101228272A (zh) * 2005-04-20 2008-07-23 生物载体株式会社 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗
KR20080031167A (ko) * 2005-04-20 2008-04-08 디나벡크 가부시키가이샤 알츠하이머병 치료용의 고도로 안전한 비강투여용 유전자백신
WO2006126682A1 (ja) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルツハイマー病の予防・治療用ワクチン
DE602006018744D1 (de) 2005-06-23 2011-01-20 Keygene Nv Strategien mit hohem durchsatz zur identifizierung und zum nachweis von polymorphismen
US20090170713A1 (en) 2005-09-29 2009-07-02 Keygene N.V. High throughput screening of mutagenized populations
US10316364B2 (en) 2005-09-29 2019-06-11 Keygene N.V. Method for identifying the source of an amplicon
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
ES2558124T3 (es) 2005-12-22 2016-02-02 Keygene N.V. Procedimiento para detección de polimorfismos basada en AFLP de alto rendimiento
ES2829295T3 (es) 2006-04-04 2021-05-31 Keygene Nv Detección de alto rendimiento de marcadores moleculares basados en AFLP y secuenciación de alto rendimiento
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5792625B2 (ja) 2009-11-02 2015-10-14 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
JP5697044B2 (ja) * 2010-01-08 2015-04-08 国立大学法人京都大学 タウオパチー治療用ワクチン
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
RU2683497C2 (ru) * 2012-04-18 2019-03-28 Дзе Чилдрен'З Хоспитал Оф Филадельфия Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CA3048313A1 (en) 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
EP3856762A1 (de) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin-expressionskonstrukte mit gentechnisch veränderten promotoren und verfahren zu deren verwendung
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
WO2022026409A1 (en) 2020-07-27 2022-02-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
JP2024500768A (ja) * 2020-12-18 2024-01-10 ベイラー カレッジ オブ メディスン 凝集抑制のためのＡβ変異体の伝達
EP4433490A2 (de) 2021-11-17 2024-09-25 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen im zusammenhang mit glucosylceramidase-beta-mangel
WO2024163012A1 (en) 2023-02-02 2024-08-08 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514333A (ja) * 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO2000039310A1 (en) * 1998-12-29 2000-07-06 The University Of Georgia Research Foundation, Inc. Rubredoxin fusion proteins, protein expression system and methods
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
WO2002036614A2 (en) * 2000-11-01 2002-05-10 Insight Biotechnology Limited Peptides for use in the treatment of alzheimer's disease
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CN100450551C (zh) * 2002-11-29 2009-01-14 中国医学科学院基础医学研究所 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途

Also Published As

Publication number Publication date
JP4888876B2 (ja) 2012-02-29
US8318687B2 (en) 2012-11-27
CA2529179A1 (en) 2004-12-23
EP1634956A1 (de) 2006-03-15
EP1634956A4 (de) 2007-01-24
DE602004026867D1 (de) 2010-06-10
US20090004144A1 (en) 2009-01-01
RU2335542C2 (ru) 2008-10-10
AU2004248014A1 (en) 2004-12-23
WO2004111250A1 (ja) 2004-12-23
AU2004248014B2 (en) 2008-12-04
NZ544554A (en) 2010-06-25
EP1634956B1 (de) 2010-04-28
RU2006101149A (ru) 2006-06-27
BRPI0411321A (pt) 2006-07-18
CA2529179C (en) 2012-08-21
DK1634956T3 (da) 2010-08-16
JP2005021149A (ja) 2005-01-27
PT1634956E (pt) 2010-06-23
ES2345151T3 (es) 2010-09-16
KR20060029225A (ko) 2006-04-05

Similar Documents

Publication Publication Date Title
ATE466093T1 (de) Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
SI1317479T1 (sl) Postopki in sestavki za bolezni, povezane z amiloidozo
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
ATE529444T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
EP1731605A4 (de) Aus wt1 stammende krebsantigenpeptide
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
ATE386104T1 (de) Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
DE60035523D1 (de) Optimierte minigene und dadurch kodierte peptide
DE602004029465D1 (de) Externes Präparat zur Behandlung von Fusspilz
DE60118359D1 (de) Humanische pellino-polypeptide
EP1499349A4 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
WO2004096856A3 (en) Secreted protein family
EP1270588A4 (de) NEUESKOLLAGEN-äHNLICHES PROTEIN CLAC, DESSEN VORLäUFER UND DAFüR KODIERENDE GENE
ATE361755T1 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE60120357D1 (de) Haemophilus influenza äusseres membranprotein und verwendung davon als impstoff
ATE394420T1 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee